modelAnakinra_1
Extends from Pharmacolibrary.Drugs.ATC.L.L04AC03_1.
Information
| name: | Anakinra_1 | |
| ATC code: | L04AC03_1 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 7.8 | L |
| clearance: | 0.29 | L/h |
| other parameters in model implementation | ||
Anakinra is a recombinant, non-glycosylated human interleukin-1 receptor antagonist (IL-1Ra) protein used for the treatment of rheumatoid arthritis and other autoinflammatory conditions. Anakinra blocks the biological activity of interleukin-1 by competitively inhibiting its binding to the interleukin-1 type I receptor (IL-1RI), and is approved for use in several countries.
Pharmacokinetics
Pharmacokinetic parameters reported for patients with end-stage renal disease (ESRD) receiving subcutaneous anakinra 100 mg.
References
Urien, S, et al., & Quartier, P (2013). Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC pharmacology & toxicology 14 40–None. DOI:10.1186/2050-6511-14-40 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23915458
Liu, D, et al., & Jusko, WJ (2011). Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis. Journal of pharmacokinetics and pharmacodynamics 38(6) 769–786. DOI:10.1007/s10928-011-9219-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/22002845
Dubinsky, S, et al., & Edginton, A (2024). Physiologically Based Pharmacokinetic Modelling in Critically Ill Children Receiving Anakinra While on Extracorporeal Life Support. Clinical pharmacokinetics 63(9) 1343–1356. DOI:10.1007/s40262-024-01424-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/39331235
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)